• Sign Up

Warfarin Drug Interactions

Unlimited Physician MD/DO/PA CME

Stay up to date on the latest medical knowledge with 5923 CME activities. In these online self-assessment activities, you will read our reference articles and test your knowledge with more than 6445 hours of CME.


6 Month Unlimited Physician MD/DO/PA CME

$199

Access to all the Physician MD/DO/PA CME activities in all specialties.
1 Year Unlimited Physician MD/DO/PA CME

$299

Access to all the Physician MD/DO/PA CME activities in all specialties.

  Warfarin Drug Interactions

Credits: 1.00   Post-Assessment Questions:  7

Release Date: 5 Oct 2020
Expiration Date: 5 May 2021
Last Reviewed: 5 May 2020
Estimated Time To Finish: 60 Minutes

Need Help?  If you have a system or content concerns, please contact support@statpearls.com, or call (727) 289-9796.

Activity Description

Warfarin has FDA approval for the prophylaxis and treatment of venous thrombosis and its complications, such as a pulmonary embolus. It is also indicated to prevent thromboembolic complications associated with conditions such as atrial fibrillation, cardiac valve replacement, and inherited genetic factors like C and S protein deficiency or Factor V Leiden. Additionally, warfarin is FDA approved as an adjunct to reduce the risk of myocardial infarction (MI) and other thromboembolic events in high-risk patients. However, warfarin falls in the narrow therapeutic index drug category and is subject to numerous interactions. This activity outlines the indications, mechanism of action, interactions, significant adverse effects, contraindications, toxicity, and monitoring of warfarin so providers can direct patient therapy where anticoagulation is indicated as part of the interprofessional team.

Target Audience

This activity has been designed to meet the educational needs of physicians.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the mechanism of action of warfarin.
  • Review the agents that can either increase or decrease the anticoagulant effect of warfarin.
  • Summarize the target INR levels for warfarin therapy based on conditions that affect INR targets.

Author(s) / Contributors Disclosure of Conflicts of Interest

Each author, editor, faculty and planning committee member have completed a disclosure form indicating that neither they nor their spouse/partner has a financial interest/arrangement or affiliation that could be perceived as a real or apparent conflict of interest related to the content of this activity.

COMMERCIAL SUPPORT: This activity has received NO commercial support.

Contributors

Hover over the contributor names to see details and disclosures of any financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Authors: Marsha Crader, Tracy Johns
Editors: Justin Arnold
Editors-In-Chief: Jon ParhamJon SivoravongChristine Burkhardt
Chief Medical Reviewer: Mark Pellegrini
Nurse Planner/Reviewer/Editor: Lisa Haddad
Pharmacy Planner/Reviewer/Editor: Mark Pellegrini
Physician Planner/Reviewer/Editor: Scott Dulebohn

Continuing Education Accreditation Information


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Quillen College of Medicine, East Tennessee State University, and StatPearls, LLC. The Quillen College of Medicine, East Tennessee State University is accredited by the ACCME to provide continuing medical education for physicians.

Quillen College of Medicine, East Tennessee State University designates this activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Cancellation Policy: Cancellations must be received in writing and a money-back guarantee is provided if not completely satisfied.

  • StatPearls and ETSU reserve the right to cancel any course due to unforeseen circumstances. StatPearls and ETSU will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

  • StatPearls and ETSU are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

  • Computer Requirements:  Internet Access
  • E-mail Address

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the required accreditation information:  Target audience, learning objectives, and disclosure information.
  3. Complete the entire self-study activity.
  4. Complete the post-test assessments.
  5. Successfully pass the post-test with a minimum score of 100%.
  6. Complete the evaluation form.
  7. Obtain a certificate.

StatPearls and ETSU adhere to ACCME Standards regarding commercial support of continuing medical education. It is the policy of StatPearls and ETSU that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Media Usage Rights

The contributors and editors of StatPearls have attested that all associated media (images and video) have been legally cleared for use with this activity.  All copyrights are reserved.

    Average Rating: 3.00

    5 Star
    4 Star
    3 Star
    2 Star
    1 Star